BSBE(SZ:300406) Xin Lang Cai Jing·2026-02-26 01:36Group 1 - The core viewpoint of the news is that Jiukang Bio has experienced a decline in both revenue and net profit for the first nine months of 2025, with a significant drop of 18.24% in revenue and 27.03% in net profit year-on-year [2] - As of February 25, Jiukang Bio's financing balance reached 2.08 billion yuan, with a net financing outflow of 137.65 million yuan on that day, indicating a high level of financing activity [1] - The company has a diverse revenue structure, with 95.09% of its income coming from in vitro diagnostic reagents, while other segments contribute significantly less [1] Group 2 - As of September 30, 2025, Jiukang Bio had 18,100 shareholders, a decrease of 2.48% from the previous period, while the average number of circulating shares per person increased by 2.54% to 23,502 shares [2] - The company has distributed a total of 1.33 billion yuan in dividends since its A-share listing, with 701 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 8.3446 million shares, having reduced its holdings by 1.4085 million shares compared to the previous period [3]